| The Importance of Busulfan Pharmacokinetics for Improving the Safety and Antitumor Efficacy of Pretransplant Conditioning Therapy for Myeloid Malignancies |
|
2005 |
| Improving Pretransplant Conditioning Therapy Through Busulfan Pharmacokinetics. |
|
2005 |
| Long-term quality of life is not affected by age in AML/MDS patients after allogeneic hematopoietic stem cell transplantation |
|
2005 |
| Extracorporeal Photochemotherapy for the treatment of chronic graft-versus-host disease. |
|
2005 |
| Hyperacute GVHD: analysis of risk factors, clinical manifestations, and outcomes. |
|
2005 |
| Lack of impact of comorbidities on outcomes of allogeneic stem cell transplantation for refractory acute myelogenous leukemia / myelodysplastic syndrome. |
|
2005 |
| Prognostic factors for allogeneic stem cell transplantation for untreated first relapse of acute myelogenous leukemia/myelodysplastic syndrome |
|
2005 |
| Andersson BS . Pretransplant conditioning with IV busulfan (Bu) and fludarabine (Flu) as alternative to Bu and cyclophosphamide (Cy) - a safe myeloablative regimen with high antileukemic efficacy in AML/MDS |
|
2005 |
| Vaccination With The PR1 Leukemia-Associated Antigen Can Induce Complete Remission In Patients With Myeloid Leukemia. |
|
2004 |
| Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H. |
|
2004 |
| Second Autologous Or Allogeneic Transplantation After The Failure Of First Autograft In Multiple Myeloma. |
|
2004 |
| Allogeneic stem cell transplantation with reduced-intensity, fludarabine based conditioning in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen on survival. |
|
2004 |
| Effect of high-dose rituximab on peripheral blood stem cell mobilization in intermediate grade non-Hodgkin s lymphomas. |
|
2004 |
| Hyperacute Graft-Versus-Host Disease: Analysis of risk factors, clinical manifestations and outcomes |
|
2004 |
| A novel triple purge strategy for eliminating chronic Myelogenous leukemia (CML) cells from autografts. |
|
2004 |
| IV busulfan (Bu) with fludarabine (Flu) or cyclophosphamide (Cy) - comparing ablative conditioning regimens for allogeneic transplantation in AML/MDS |
|
2004 |
| Allogeneic hematopoietic stem cell transplantation (HSCT) for patients aged 65 years or older with MAL and MDS. |
|
2004 |
| Once daily busulfan (BU) and fludarabine (FLU) with allogeneic stem cell transplantation (Allosct) in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS): clinical results and pharmacokinetics |
|
2003 |
| Long-term follow-up of patients with AML and MDS treated with reduced-intensity or non-myeloablative conditioning regimens and allogeneic hematopoietic stem cell transplantation. |
|
2003 |
| Analysis of One Antigen Mismatched Related Transplants for Advanced Stage Myeloid Leukemias. |
|
2002 |
| Reduced toxicity conditioning therapy with Fludarabine and IV Busulfan ± ATG for allogeneic transplantation in AML and MDS; preliminary results. |
|
2002 |
| Using two mismatched unrelated donor cord blood units for transplantation: analysis of chimerism and immune reconstitution. |
|
2001 |
| Treatment of Newly Diagnosed Acute Myelogenous Leukemia in Patients 80 years and Above. |
|
1995 |
